Harry P Erba

Harry P Erba

UNVERIFIED PROFILE

Are you Harry P Erba?   Register this Author

Register author
Harry P Erba

Harry P Erba

Publications by authors named "Harry P Erba"

Are you Harry P Erba?   Register this Author

68Publications

1936Reads

37Profile Views

Shifting paradigms in the treatment of older adults with AML.

Semin Hematol 2019 Apr 27;56(2):110-117. Epub 2019 Feb 27.

Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Durham, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2019.02.002DOI Listing
April 2019

Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.

Leuk Res 2018 11 27;74:64-67. Epub 2018 Sep 27.

Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183022
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.09.014DOI Listing
November 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

J Clin Oncol 2017 Aug 9;35(24):2745-2753. Epub 2017 May 9.

Mikkael A. Sekeres and Aziz Nazha, Cleveland Clinic, Cleveland; Clara D. Bloomfield, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Megan Othus and Anna Moseley, SWOG Statistical Center; Min Fang and Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center, Seattle, WA; Alan F. List, H. Lee Moffitt Cancer Center, Tampa, FL; Olatoyosi Odenike, University of Chicago, Chicago; Mario R. Velasco, Heartland NCORP/Cancer Care Specialists of Central Illinois, Decatur, IL; Richard M. Stone, Dana Farber Cancer Institute; Eyal C. Attar, Massachusetts General Hospital, Boston, MA; Steven D. Gore, Yale University, New Haven, CT; Mark R. Litzow, Mayo Clinic, Rochester, MN; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto; Elina K. Cook, Alyssa H. Cull, and Michael J. Rauh, Queen's University, Kingston, Ontario, Canada; Diane Roulston, University of Michigan, Ann Arbor, MI; Yanming Zhang, Memorial Sloan-Kettering Cancer Center, New York, NY; Rakesh Gaur, Kansas City National Cancer Institute Community Oncology Research Program, Prairie Village, KS; Ehab Atallah, Medical College of Wisconsin, Milwaukee, WI; and Harry P. Erba, University of Alabama, Birmingham, AL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562170PMC
August 2017

Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Leuk Res 2016 Mar 15;42:68-74. Epub 2016 Jan 15.

Oncology Research Institute, Loyola University Health Sciences Division, Maywood, IL 60153, United States; Division of Hematology & Oncology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779662PMC
March 2016

Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Haematologica 2015 Oct 9;100(10):e409-11. Epub 2015 Jul 9.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.130013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591777PMC
October 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

J Clin Oncol 2015 Apr 2;33(11):1252-7. Epub 2015 Mar 2.

Richard M. Stone, Emanuele Mazzola, and Donna Neuberg, Dana-Farber Cancer Institute, Boston; Ante S. Lundberg, Antisoma, Cambridge, MA; Steven L. Allen, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success; Meir Wetzler, Roswell Park Cancer Institute, Buffalo; Martin S. Tallman, Memorial Sloan Kettering Cancer Center, New York, NY; Arnaud Pigneux, Hopital Haut-Leveque, Pessac, France; Robert K. Stuart, Medical University of South Carolina, Charleston, SC; David Rizzieri, Duke University Medical Center, Durham; Bayard Powell, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC; Harry P. Erba, University of Michigan Health System, Ann Arbor, MI; Lloyd Damon, University of California San Francisco, San Francisco, CA; Jun-Ho Jang, Samsung Medical Center, Seoul, Korea; Krzysztof Warzocha, Institute of Hematology and Transfusiology, Warsaw, Poland; Támas Masszi, Szent Istvan and Szent Laszlo Corporate Hospital, Budapest; Miklos Egyed, Kaposi Mor County Teaching Hospital, Kasposvar, Hungary; Mikkael A. Sekeres, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Heinz-August Horst, Universitatsklinikum Schleswig-Holstein, Kiel, Germany; Dominik Selleslag, Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium; Scott R. Solomon, Blood and Marrow Transplant Program and Northside Hospital, Atlanta, GA; and Parameswaran Venugopal, Rush University Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/02/26/JCO.2014.57
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.0952
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.0952DOI Listing
April 2015

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.

Authors:
Harry P Erba

Am J Hematol 2015 Mar 30;90(3):242-9. Epub 2015 Jan 30.

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham (UAB) and UAB Comprehensive Cancer Center, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23902DOI Listing
March 2015

Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014.

Curr Opin Hematol 2015 Mar;22(2):108-15

aDivision of Hematology/Oncology, The Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin bDivision of Hematology/Oncology, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000120DOI Listing
March 2015

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.

Authors:
Harry P Erba

Leuk Res 2015 Feb 9;39(2):183-91. Epub 2014 Dec 9.

Division of Hematology/Oncology, Internal Medicine, University of Alabama at Birmingham, 1720 Second Avenue South, Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2014.11.027DOI Listing
February 2015

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

J Clin Oncol 2014 Apr 24;32(12):1242-8. Epub 2014 Mar 24.

Thomas Prebet, James Herman, Lisa Malick, and Steven D. Gore, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Zhuoxin Sun, Dana-Farber Cancer Institute, Boston, MA; Maria E. Figueroa and Ari Melnick, Weill Cornell Medical College; Janice Gabrilove, Mount Sinai School of Medicine; Martin S. Tallman, Leukemia Service, Memorial Sloane-Kettering Cancer Center, New York; Elisabeth Paietta, North Division, Montefiore Medical Center, Bronx, NY; Rhett Ketterling and Mark Litzow, Mayo Clinic, Rochester, MN; Peter L. Greenberg, Stanford University Cancer Center, Stanford, CA; Mark Juckett, University of Wisconsin, Madison, WI; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Magdalena Czader, Indiana University Cancer Center, Indianapolis, IN; and Harry P. Erba, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986386PMC
April 2014

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Clin Cancer Res 2014 Jan 31;20(2):490-8. Epub 2013 Oct 31.

Authors' Affiliations: The University of Chicago; Decatur Memorial Hospital, Decatur; Illinois Cancer Care, Peoria; Loyola University Medical Center, Maywood, Illinois; University of California, San Francisco, San Francisco; City of Hope, Duarte, California; University of Michigan Medical Center, Ann Arbor, Michigan; Medical College of Wisconsin, Milwaukee, Wisconsin; and National Cancer Institute, Rockville, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310865PMC
January 2014

Expert insights into the contemporary management of older adults with acute myeloid leukemia.

Cancer Control 2013 Oct;20(4 Suppl):5-16

MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/107327481302004s02DOI Listing
October 2013

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Expert Rev Anticancer Ther 2012 Oct;12(10):1289-97

Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636990PMC
October 2012

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Clin Adv Hematol Oncol 2011 Oct;9(10):734-45

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
October 2011

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.

Cancer 2011 Mar 19;117(6):1253-61. Epub 2010 Oct 19.

Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25686DOI Listing
March 2011

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.

Expert Opin Ther Targets 2011 Mar 10;15(3):253-64. Epub 2011 Jan 10.

Cambridge University, Medicine, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2011.550877DOI Listing
March 2011

Has there been progress in the treatment of older patients with acute myeloid leukemia?

Authors:
Harry P Erba

Best Pract Res Clin Haematol 2010 Dec 1;23(4):495-501. Epub 2010 Nov 1.

University of Michigan Medical School, Ann Arbor, 48109-5848, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2010.09.012DOI Listing
December 2010

Prognostic factors in elderly patients with AML and the implications for treatment.

Authors:
Harry P Erba

Hematology Am Soc Hematol Educ Program 2007 :420-8

Division of Hematology and Oncology, University of Michigan Health System, 1500 East Medical Center Drive, C348 Med Inn Building, SPC 5848, Ann Arbor, Michigan 48109-5848, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2007.1.420DOI Listing
July 2009

In vitro and in silico analysis of annexin V binding to lymphocytes as a biomarker in emergency department sepsis studies.

Acad Emerg Med 2007 Sep 26;14(9):763-71. Epub 2007 Apr 26.

Departments of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1197/j.aem.2007.01.017DOI Listing
September 2007

Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.

Pharmacotherapy 2007 Jul;27(7):970-9

Department of Clinical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.27.7.970DOI Listing
July 2007

Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.

Authors:
Harry P Erba

Curr Hematol Rep 2004 Jan;3(1):47-53

University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, 1-355 CCGC, Box 0922, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
January 2004